Somewhat Positive Press Coverage Somewhat Unlikely to Impact Vericel (VCEL) Share Price

News articles about Vericel (NASDAQ:VCEL) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vericel earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.6510557078919 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Vericel (NASDAQ VCEL) opened at $8.15 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.50 and a quick ratio of 2.22. Vericel has a 52 week low of $2.35 and a 52 week high of $8.25. The stock has a market cap of $268.79 and a price-to-earnings ratio of -9.26.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The firm had revenue of $14.26 million for the quarter. Vericel had a negative net margin of 45.11% and a negative return on equity of 265.45%. equities research analysts anticipate that Vericel will post -0.6 earnings per share for the current fiscal year.

Several equities research analysts have issued reports on the stock. ValuEngine upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Friday. BTIG Research set a $8.00 price target on shares of Vericel and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $9.00 price target on shares of Vericel in a research note on Tuesday, January 2nd.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2018/02/02/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-vericel-vcel-share-price.html.

Vericel Company Profile

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Insider Buying and Selling by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit